目的 探讨咳喘舒片联合布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘的临床疗效。方法 选择2020年2月-2021年2月在天津宁河区医院治疗的102例支气管哮喘患者为研究对象，采用双色球法分为对照组和治疗组，每组各51例。对照组吸入布地奈德福莫特罗吸入粉雾剂（Ⅱ），2吸/次，必要时增至4吸，2次/d；治疗组在对照组的基础上口服咳喘舒片，1 g/次，3次/d。两组连续治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善时间，血清白细胞介素-5（IL-5）、IL-17、基质金属蛋白酶-8（MMP-8）、IL-21和IL-22水平及ACQ-7、ACT和Marks-AQLQ评分。结果 经治疗，对照组有效率为84.31%，显著低于治疗组的98.04%（P<0.05）。经治疗，治疗组症状改善时间明显早于对照组（P<0.05）。经治疗，两组血清IL-5、IL-17、MMP-8、IL-21、IL-22水平均显著下降（P<0.05），且治疗组降低更明显（P<0.05）。经治疗，两组ACQ-7评分和Marks-AQLQ评分明显下降，而哮喘控制ACT评分明显升高（P<0.05），且治疗组患者评分明显好于对照组（P<0.05）。结论 咳喘舒片联合布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘可有效改善患者临床症状，降低气道炎症反应，改善患者生存质量。

Objective To explore the clinical efficacy of Kechuanshu Tablets combined with budesonide formoterol in the treatment of bronchial asthma. Methods Patients (102 cases) with bronchial asthma in Tianjin Ninghe District Hospital from February 2020 to February 2021 were divided into control and treatment groups based on union lotto method, and each group had 51 cases. Patients in the control group were administered with Budesonide and Formoterol Fumarate Powder for Inhalation (II), 2 press/time, and increased to 4 press if necessary, twice daily. Patients in the treatment group were po administered with Kechuanshu Tablets, 1 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, the serum levels of IL-5, IL-17, MMP-8, IL-21 and IL-22, and the scores of ACQ-7, ACT, and Marks-AQLQ in two groups before and after treatment were compared. Results After treatment, the effective rate in the control group was 84.31%, which was significantly lower than 98.04% in the treatment group (P<0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the serum levels of IL-5, IL-17, MMP-8, IL-21 and IL-22 were significantly decreased in two groups (P<0.05), especially in the treatment group (P<0.05). After treatment, the scores of ACQ-7 and Marks-AQLQ in two groups were significantly decreased, while the ACT score of asthma control were significantly increased (P<0.05), and these scores in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Kechuanshu Tablets combined with budesonide formoterol in the treatment of bronchial asthma can effectively improve the clinical symptoms, reduce airway inflammation and improve the quality of life of patients.

R974

天津市卫生和计划生育委员会科研课题（2016RB16251）